Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials

NCT05564390 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT05564390
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05564390 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Recruiting
Start date
June 18, 2024
Completion date
May 15, 2029
Enrollment
2,000 (estimated)
Sites
355

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, acute myeloid leukemia arising from previous myelodysplastic/myeloproliferative neoplasm, acute myeloid leukemia post cytotoxic therapy, acute myeloid leukemia, myelodysplasia-related, myelodysplastic syndrome